Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Feb 28, 2005; 11(8): 1109-1114
Published online Feb 28, 2005. doi: 10.3748/wjg.v11.i8.1109
Published online Feb 28, 2005. doi: 10.3748/wjg.v11.i8.1109
Pt | Age (yr) | Sex | Therapy drug | Duration (d)1 | Condition | History of immunosuppresive or cytotoxic therapy | Outcome |
Patients who received early introduction of high-dose corticosteroids | |||||||
1. | 27 | M | MPSL/PSL | 1 | Ulcerative colitis | + | Death |
2. | 36 | M | PSL | 2 | - | Re covery | |
3. | 41 | F | PSL | 3 | - | Recovery | |
4. | 27 | M | PSL | 4 | - | Recovery | |
5. | 41 | F | PSL | 4 | Schizophrenia | - | Recovery |
6. | 33 | M | PSL+Lam | 4 | - | Recovery | |
7. | 68 | F | PSL+Lam | 4 | Non-Hodgkin’s lymphoma | + | Recovery |
8. | 56 | M | PSL | 5 | - | Recovery | |
9. | 57 | F | PSL | 5 | - | Recovery | |
10. | 39 | M | PSL | 5 | Acute lymphocytic leukemia | + | Recovery |
11. | 43 | M | PSL | 10 | - | Recovery | |
Patients who did not receive early introduction of high-dose corticosteroids | |||||||
12. | 49 | F | PSL+IFN | 14 | Non-Hodgkin’s lymphoma | + | Death |
13. | 59 | F | PSL | 14 | - | Death | |
14. | 47 | M | PSL+Lam | 14 | Ulcerative colitis | + | Death |
15. | 58 | M | PSL | 15 | - | Death | |
16. | 59 | M | PSL | 17 | - | Death | |
17. | 36 | F | MPSL/PSL+IFN | 28 | Breast cancer | + | Death |
18. | 68 | F | PSL | 120 | Pemphigoid | + | Death |
19. | 41 | M | glycyrrhizin | - | Recovery | ||
20. | 55 | M | glycyrrhizin | - | Recovery | ||
21. | 59 | M | glycyrrhizin | - | Death | ||
22. | 28 | M | glycyrrhizin | Mental retardation | - | Death |
Pt | PT(%) | ALT(IU/L) | T-bili(mg/dL) | HBeAg/HBeAb | IgM-HBc(cut-off index) | HBV DNApolymerase (cpm) | HBV DNA(Meq/mL) | Liver histology |
Patients who received early introduction of high-dose corticosteroids | ||||||||
1. | 16 | 1698 | 9.5 | -/+ | 2.6 | 10 | ND | ND |
2 | 31 | 2689 | 3 | +/- | 0.3 | 3517 | ND | ND |
3 | 57 | 474 | 15.2 | -/+ | 0.2 | 50 | <0.70 | ND |
4 | 37 | 495 | 12.0 | +/- | 0.3 | 999 | 920 pg/mL | CAH (F2, severe) |
5 | 37 | 155 | 8 | -/- | 0.5 | ND | 1+ | ND |
6 | 56 | 2080 | 4.2 | +/+ | 1.8 | 595 | <0.70 | CAH (F2, severe) |
7 | 57 | 167 | 3.1 | -/+ | ND | 6425 | ND | ND |
8. | 37 | 2257 | 3.7 | -/+ | 2.3 | 28 | 20 | CAH (F3, severe) |
9 | 34 | 224 | 7.3 | +/- | 1.4 | 25 | 1.2 | ND |
10 | 56 | 399 | 3.8 | -/+ | 3.7 | 11600 | ND | Submassive necrosis |
11 | 46 | 101 | 6.4 | -/+ | 0.3 | 10 | <0.70 | LC, submassive necrosis |
Patients who did not receive early introduction of high-dose corticosteroids | ||||||||
12 | 29 | 254 | 12.6 | -/+ | 1.1 | 0 | <0.70 | ND |
13. | 34 | 2 643 | 19.3 | +/- | 1.6 | 0 | <0.70 | ND |
14. | 32 | 240 | 2.9 | -/+ | 0.5 | 12735 | 3800 | ND |
15 | 28 | 228 | 13.3 | -/+ | 3.3 | 16 | 1.1 | Submassive necrosis |
16. | 29 | 150 | 13.3 | -/+ | 0.2 | 53856 | >10000 | Submassive necrosis |
17 | 19 | 549 | 11.1 | +/- | 7.6 | 2 | 1.9 | LC, submassive necrosis |
18 | 28 | 954 | 6.3 | -/+ | ND | ND | ND | Submassive necrosis |
19. | 59 | 214 | 12.9 | +/+ | 0.4 | 5 | ND | CAH (F3, moderate) |
20 | 38 | 3620 | 7.7 | -/+ | 0.2 | 0 | <0.70 | CAH (F3, moderate) |
21. | 33 | 164 | 8.9 | +/- | ND | 7576 | ND | LC, submassive necrosis |
22. | 21 | 49 | 8.0 | +/- | 1.0 | 0 | <0.70 | Submassive necrosis |
- Citation: Fujiwara K, Yokosuka O, Kojima H, Kanda T, Saisho H, Hirasawa H, Suzuki H. Importance of adequate immunosuppressive therapy for the recovery of patients with “life-threatening” severe exacerbation of chronic hepatitis B. World J Gastroenterol 2005; 11(8): 1109-1114
- URL: https://www.wjgnet.com/1007-9327/full/v11/i8/1109.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i8.1109